Skip to contentC
Capricor Therapeutics, Inc.
C
CAPRCapricor Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$996.46K$996.46K−11.8% vs Q2 2016 Net Income-$3.47M-$3.47MN/M vs Q2 2016 EPS Diluted-$0.16-$0.16N/M vs Q2 2016 Operating Income-$3,378,662N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Capricor Therapeutics, Inc. · CIK 1133869 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,710,764N/M Margins · derivedOperating margin-339.1%+69.2 pt vs Q2 2016
Net margin-348.4%+66.6 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 14, 2017 · 45 d after period end